HBM-7008 is under clinical development by Harbour BioMed (Guangzhou) and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HBM-7008’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HBM-7008 overview
Bi-specific monoclonal antibody is under development for the treatment of ovarian cancer, lung cancer, endometrial cancer, cervical cancer, squamous non-small cell lung cancer, cholangiocarcinoma, esophageal cancer, urothelial cell carcinoma, head and neck cancer squamous cell carcinoma, non-small cell lung cancer, triple-negative breast cancer and solid tumor. It targets tumor necrosis factor receptor superfamily member 9 (CD137) and tumor associated antigen 1 (TAA1) and B7H4. The drug candidate is developed based on the heavy chain antibody immune cell adapter double antibody platform (HBICE). It is administered through intravenous route.
Harbour BioMed (Guangzhou) overview
Harbour BioMed., a clinical-stage biopharmaceutical company that engaged in the provision of technology enabled healthcare services. The company is headquartered in China.
For a complete picture of HBM-7008’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
